Warrant exercise and trust sale at NewAmsterdam Pharma (NASDAQ: NAMS)

Rhea-AI Filing Summary

NewAmsterdam Pharma Company N.V. resale filing shows planned and recent transfers of Ordinary Shares. The filing lists a warrant exercise issuing 44,619 Ordinary Shares on 03/09/2026 for cash. It also records that The LG Lange III Trust sold 28,186 Ordinary Shares on 03/06/2026 for $828,849.41.

This Form 144 excerpt documents resale activity by a trust and a warrant-related issuance; cash‑flow treatment for proceeds beyond the warrant exercise is not detailed in the excerpt.

Insights

Securities Lawyer

Form 144 documents resale and a warrant exercise; it is a regulatory notice of proposed sale.

Form 144 is a notice required when certain holders propose to sell restricted or control securities. The excerpt lists a warrant exercise issuing 44,619 Ordinary Shares on 03/09/2026 for cash and a prior sale by The LG Lange III Trust of 28,186 shares on 03/06/2026.

Timing and effectiveness constraints for any resale depend on Rule 144 compliance (holding periods, current public information, volume limits); the excerpt does not state those compliance details.

Equity Capital Markets Analyst

Transaction sizes are modest; the filing signals limited near‑term resale activity by a trust and an issuance from exercise.

The disclosed sale of 28,186 shares for $828,849.41 and the 44,619-share warrant exercise are small in typical equity-capital terms. The excerpt does not tie these figures to shares outstanding or dilution metrics.

Subsequent filings or company disclosures would be needed to assess any material overhang or impact on free float.

03/11/2026 - 04:08 PM

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	J.P. Morgan Securities LLC 270 Park Avenue - 10th Floor New York NY 10017	44619	1395236.13	114975422	03/11/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	03/09/2026	Warrant Exercise	Issuer			44619	03/09/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
The LG Lange III Trust DTD 10/12/16 Care of NewAmsterdam Pharma Company N.V. Gooimeer 2-35 DC Naarden P7 1411	Ordinary Shares	03/06/2026	28186	828849.41

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the NAMS Form 144 disclose about recent sales?

The filing records that The LG Lange III Trust sold 28,186 Ordinary Shares on 03/06/2026, generating $828,849.41. This is a reported resale transaction by the trust as shown in the excerpt.

Does the NAMS filing show any share issuance from option or warrant exercise?

Yes. The excerpt lists a warrant exercise issuing 44,619 Ordinary Shares on 03/09/2026 for cash. The entry is labeled as a warrant exercise in the securities-to-be-sold section.

Who is the selling holder named in the NAMS excerpt?

The selling holder named is The LG Lange III Trust DTD 10/12/16 (care of NewAmsterdam Pharma Company N.V.), which the excerpt shows sold 28,186 Ordinary Shares on 03/06/2026.

Does the Form 144 excerpt state how proceeds will be used?

The excerpt specifies the warrant exercise was for cash, but it does not state how the proceeds from the exercise or the trust sale will be used. No use-of-proceeds detail appears in the provided text.

Are volume or holding-period compliance details included in the NAMS excerpt?

No. The provided excerpt lists transactions and amounts but does not include Rule 144 holding-period, volume limit, or public-information compliance statements. Those details are not present in the excerpt.